ALEXANDRIA, Va. and
CAMBRIDGE, Mass., Sept. 16, 2020 /PRNewswire/ -- Oxford Finance LLC
("Oxford"), a specialty finance firm that provides senior debt to
life sciences and healthcare services companies worldwide, has
announced the closing of a $15
million senior secured term loan with Vedanta Biosciences,
Inc. ("Vedanta" or "the Company"), a clinical-stage
biopharmaceutical company developing a new category of therapies
for immune-mediated diseases based on defined bacterial consortia.
The funds will be used for general working capital and to advance
the development pipeline.
![Oxford Finance Logo Oxford Finance Logo](https://mma.prnewswire.com/media/440345/Oxford_Finance_Logo.jpg)
The human microbiome is increasingly recognized as a key factor
in the development and regulation of the immune system and
protection from infectious diseases. Vedanta designs medicines
based on consortia of human commensal bacteria to treat disease,
using insights from microbial ecology, mucosal immunology, and
human interventional studies. Vedanta's breakthrough science has
led to the creation of a unique platform to develop defined
consortia manufactured from pure, clonal strains, eliminating the
need to source donor material.
"Vedanta's scientists have contributed foundational discoveries
to the microbiome field," said Christopher
A. Herr, senior managing director at Oxford Finance. "Oxford
is pleased to provide the funds to support the Company's
differentiated approach, which eliminates the need for donor
material and eliminates the risk of passing pathogens to
patients."
About Oxford Finance LLC
Oxford Finance is a specialty finance firm providing senior
secured loans to public and private life sciences and healthcare
services companies worldwide. For over 20 years, Oxford has
delivered flexible financing solutions to its clients, enabling
these companies to maximize their equity by leveraging their
assets. In recent years, Oxford has originated over $6 billion in loans, with lines of credit ranging
from $5 million to $150 million. Oxford is headquartered in
Alexandria, Va., with additional
offices in San Diego, Calif.;
Palo Alto, Calif.; and the greater
Boston and New York City areas. For more information,
visit https://oxfordfinance.com/
About Vedanta Biosciences
Vedanta Biosciences is leading the development of a new
category of oral therapies based on rationally defined consortia of
bacteria derived from the human microbiome. The company's
clinical-stage pipeline includes product candidates being evaluated
for the treatment of high-risk
C. difficile infection, inflammatory bowel
diseases, advanced or metastatic cancers, and food allergy. These
investigational therapies are grounded in pioneering research –
published in leading journals including
Science, Nature, and Cell
– to identify beneficial bacteria that live symbiotically
within the healthy human gut, fight pathogens and induce a range of
potent immune responses. Vedanta Biosciences controls a
foundational portfolio of more than 40 patents and has built what
is believed to be the world's biggest library of bacteria derived
from the human microbiome. Proprietary capabilities include
deep expertise in consortium design, vast datasets from human
interventional studies and cGMP-compliant manufacturing of oral
live biotherapeutics containing pure, clonally derived bacterial
consortia in powdered form. Vedanta Biosciences was founded
by PureTech Health (LSE: PRTC) and a global team of
scientific co-founders who pioneered Vedanta's modern understanding
of the cross-talk between the microbiome and the immune system.
Media Contacts
Selma Bašić
Oxford Finance LLC
703-519-4900 Tel
media@oxfordfinance.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oxford-finance-closes-15-million-credit-facility-with-vedanta-biosciences-inc-301132510.html
SOURCE Oxford Finance LLC